BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
AMGN upcoming catalysts
Amgen: 5 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (3 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 17 readout(s) and 3 FDA event(s). Subscribe to AMGN (.ics).
Drugs: Anvumetostat, Dazodalibep, Docetaxel, ABP 234, Pembrolizumab, AMG 732, Maridebart Cafraglutide, sotorasib, Midazolam, Nivolumab
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P1/P2 | Amgen AMGN | NCT05094336 A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | Advanced MTAP-null Solid Tumors | active not recruiting | 329 |
| 2026-12-14 est. | P3 | Amgen AMGN | NCT06430866 Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | active not recruiting | 163 |
| 2027-01-06 est. | P1/P2 | Amgen AMGN | NCT06401044 A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease | Thyroid Eye Disease | active not recruiting | 94 |
| 2027-01-21 est. | P3 | Amgen AMGN | NCT06858839 Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Obesity | active not recruiting | 3853 |
| 2027-01-21 est. | P3 | Amgen AMGN | NCT06858878 Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | active not recruiting | 1105 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-10-22 | FDA approval | approved | AMGEN INC AMGN | PAVBLU | Approved 2026-10-22: PAVBLU (BLA761298 ORIG2) |
| 2026-10-09 | FDA approval | approved | AMGEN INC AMGN | REPATHA | Approved 2026-10-09: REPATHA (BLA125522 SUPPL47) |
| 2025-11-19 | FDA approval | approved | AMGEN INC AMGN | IMDELLTRA | Approved 2025-11-19: IMDELLTRA (BLA761344 SUPPL1) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-31 est. | P2 | Amgen AMGN | NCT06593522 A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) | MTAP-deleted NSCLC | active not recruiting | 61 |
| 2026-10-22 est. | P3 | Amgen AMGN | NCT06245408 A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State | Sjögren's Syndrome (SS) | active not recruiting | 434 |
| 2026-08-12 | P3 | Amgen AMGN | NCT06088199 A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis | Plaque Psoriasis | completed | 51 |
| 2026-07-23 | P3 | Amgen AMGN | NCT06104124 A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity | Sjogren's Syndrome | completed | 651 |
| 2026-07-01 | P3 | Amgen AMGN | NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (A | Atopic Dermatitis | terminated | 2621 |
| 2026-05-29 | P1/P2 | Amgen AMGN | NCT03600883 A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (Cod | KRAS p.G12C Mutant Advanced Solid Tumors | completed | 713 |
| 2026-05-14 | P2 | Amgen AMGN | NCT06376045 A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma | Asthma | terminated | 317 |
| 2026-04-28 | P2 | Amgen AMGN | NCT06312020 A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome | Sjogren's Syndrome | terminated | 209 |
| 2026-04-17 | P3 | Amgen AMGN | NCT06527404 A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis | Prurigo Nodularis | terminated | 469 |
| 2026-03-10 | P3 | Amgen AMGN | NCT03937154 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | Chemotherapy-induced Thrombocytopenia | active not recruiting | 145 |
| 2026-02-25 | P1/P2 | Amgen AMGN | NCT05975073 A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors | MTAP-null Non-Small-Cell Lung Cancer; MTAP-null Solid Tumors | completed | 53 |
| 2026-01-28 | P1/P2 | Amgen AMGN | NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | Solid Tumors | terminated | 260 |
| 2026-01-06 | P2 | Amgen AMGN | NCT06054113 Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) | B Precursor Acute Lymphoblastic Leukemia; Relapsed/Refractory B Precursor Acute Lymphoblastic Leukem | active not recruiting | 18 |
| 2025-12-23 | P3 | Amgen AMGN | NCT06248619 A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyro | Thyroid Eye Disease | active not recruiting | 89 |
| 2025-11-21 | P1/P2 | Amgen AMGN | NCT05322577 A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junc | Gastric Cancer; Gastroesophageal Junction Cancer | terminated | 72 |
| 2025-11-20 | P3 | Amgen AMGN | NCT05565560 A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | completed | 21 |
| 2025-11-19 | P3 | Amgen AMGN | NCT03836040 Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine | Migraine | active not recruiting | 457 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.